Q3, 2019 New Target Investment Snapshot

To our investors and syndicate allies,  

Global Medical Holdings has one company that we are proud to present.  The company is listed in detail below in this email and in the summary here:

Neumentum, Inc.:  Neumentum is a privately held life science company focused on non-opioid alternatives to address pain. Neumentum is currently preparing for its forthcoming phase 3 trials of a non-opioid, acute, post-operative pain medication that is being developed under a 505(b)(2) FDA designation.

______________________________________________________________

Neumentum, Inc.

A Non-Opioid Pain Company.

GMH Funding Amount:

$400k Convertible Note Round

$25k Unit Minimum

Investment Closing Date: Sept. 30, 2019

Neumentum, Inc. is headquartered in Palo Alto, CA and is a privately held life science company focused on non-opioid alternatives to address pain.  Neumentum is currently preparing for its forthcoming phase 3 trials of a non-opioid, acute, post-operative pain medication that is being developed under a 505(b)(2) FDA designation.  The lead product is a novel reformulation of the well-known approved non-opioid drug Ketorolac (trade name: Toradol),  from a short-acting injectable drug to a pre-mixed bag which provides a continuous infusion for a full 24 hours, resulting in smooth pharmacokinetics and sustained pain relief, thereby reducing the need for opioid intervention.  With potency equivalent to morphine, Toradol is already the most widely used non-opiate pain medication available for moderate-to–severe acute pain, especially in the post-operative setting.   In 2017, there were approximately, 45 million doses of this drug administered in the US, which accounted for approximately 10% of the total analgesics used in post-operative pain. The use of this drug has seen tremendous growth in use in the last year (18% growth year over year), and this growth is anticipated to continue as healthcare providers increasingly seek to avoid prescribing opioids.

Neumentum’s formulation of Ketorolac seeks to address many shortfalls of existing products by eliminating peaks and valleys of traditional Ketorolac administration, resulting in pain relief that is not only opioid-sparing, but also NSAID-sparing. If achieved, these innovations in delivery would enable more efficient and cost-effective care as well as better pain management and patient outcomes.  It fits ideally into the growing desire of hospitals to reduce and if possible replace opioids, as well as the economic pressure to reduce hospital stay to 24 hours for many post-surgical patients.

This round of financing will allow the company to accelerate the PK/Bioavailability study for Toradol PMB (Pre Mixed Bag), support preparation for the phase 3 trials, and support on-going business development activity, including a potential major in-licensing opportunity.

The Company’s management team is led by R. Scott Shively, CEO, who has more than 25 years’ experience working in pain in many roles, including Head of Pfizer’s $7B commercial pain portfolio where he developed and grew the Lyrica franchise. Additionally, Mr. Shively was instrumental in the $1B acquisition of Nucynta from J&J, and its subsequent relaunch at Depomed. Mr. Shively is joined by Dr. Joseph Pergolizzi, Jr. as Executive Chairman. Dr. Pergolizzi is an internationally recognized expert in pain medicine and has served as a top development and regulatory consultant for branded analgesics such as Nucynta, Cymbalta and Butrans. In addition, he founded and runs NEMA Research, Inc., a specialty contract research organization. 

GMH is pleased to arrange a call or meeting and will be setting up Founder Presentation Dates for you with Neumentum’s management team to provide you with a better understanding of the company’s technology and development plans. Please RSVP to any of the following dates and times:

Tuesday Sept 10, 4 to 5PM (EST)

Thursday Sept 12, 6 to 7PM (EST)

Saturdays Sept 14th, 21st, 28th, 1 to 2PM (EST)

Tuesday Sept 17, 6:30 to 7:30PM

Thursday Sept 19, 6:30 to 7:30PM

Tuesday Sept 24, 6:30 to 7:30PM

Thank you for being a part of the GMH Network of Investors,

GMH Management Team